Perillyl Alcohol in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

Completed · Phase 2

Conditions studied: Prostate Cancer

In brief

RATIONALE: Drugs used in chemotherapy use different way to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of perillyl alcohol in treating patients with metastatic prostate cancer that has not responded to hormone therapy with androgens.

Key facts

Study ID

NCT00003238

Run by

University of Wisconsin, Madison

Starts

1998-02-01

Last updated by the study team

2019-12-13

Who can join

Age: any, up to 120. Sex: male. Healthy volunteers: not accepted.

Where it is running

• Leonard C. Ferguson Cancer Center — Freeport, Illinois, United States
• Green Bay Oncology, Ltd. — Green Bay, Wisconsin, United States
• Mercy Health System — Janesville, Wisconsin, United States
• Gundersen Lutheran Medical Center — La Crosse, Wisconsin, United States
• Meriter Hospital — Madison, Wisconsin, United States
• University of Wisconsin Comprehensive Cancer Center — Madison, Wisconsin, United States
• Sinai Samaritan Medical Center - Milwaukee — Milwaukee, Wisconsin, United States
• North Central Oncology Associates, S.C. — Wausau, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.